MDxHealth SA ADR
$ 3.41
-1.73%
26 Dec - close price
- Market Cap 168,786,000 USD
- Current Price $ 3.41
- High / Low $ 3.46 / 3.31
- Stock P/E N/A
- Book Value -0.16
- EPS -0.52
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -7.20 %
- 52 Week High 5.33
- 52 Week Low 1.35
About
None
Analyst Target Price
$7.04
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-14 | 2025-05-14 | 2025-02-26 | 2024-11-06 | 2024-08-21 | 2024-05-01 | 2024-03-06 | 2023-11-08 | 2023-08-23 | 2023-05-15 | 2023-03-09 |
| Reported EPS | -0.16 | -0.14 | -0.19 | -0.14 | -0.4 | -0.42 | -0.31 | -0.39 | -0.4 | -0.3 | -0.5 | -1.1 |
| Estimated EPS | -0.17 | -0.12 | -0.13 | -0.19 | -0.25 | -0.26 | -0.3 | -0.11 | -0.19 | -0.22 | -0.5 | -0.65 |
| Surprise | 0.01 | -0.02 | -0.06 | 0.05 | -0.15 | -0.16 | -0.01 | -0.28 | -0.21 | -0.08 | 0 | -0.45 |
| Surprise Percentage | 5.8824% | -16.6667% | -46.1538% | 26.3158% | -60% | -61.5385% | -3.3333% | -254.5455% | -110.5263% | -36.3636% | 0% | -69.2308% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.126 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXH
2025-12-24 12:08:55
BTIG has reaffirmed its Buy rating and $7 price target for MDxHealth (NASDAQ:MDXH), anticipating accelerated revenue growth and improved EBITDA margins in 2026. The firm highlights MDxHealth's strong position in prostate diagnostics, particularly following the successful integration of its ExoDx acquisition, distinguishing it as an attractive small-cap growth and value stock. Despite a recent earnings miss, BTIG maintains confidence, noting the company's valuation is below peers and analyst consensus is a Strong Buy.
2025-12-24 11:09:38
BTIG has reiterated its Buy rating for MDxHealth (NASDAQ:MDXH) and maintained a $7.00 price target, anticipating accelerated revenue growth and improved adjusted EBITDA margins in 2026. The firm sees MDxHealth as a valuable small-cap growth stock in prostate diagnostics due to its "one-stop-shop" approach, strong revenue growth, and successful integration of the ExoDx acquisition. Despite a recent earnings miss, the company's liquid-based test volumes are increasing, and its Resolve test continues to outperform, contributing to a positive long-term outlook.
2025-12-23 12:09:50
BTIG has reiterated its Buy rating and $7.00 price target on MDxHealth SA (NASDAQ:MDXH), citing expectations for accelerating revenue growth and adjusted EBITDA margin expansion in 2026. The firm views MDxHealth as an attractive small-cap growth and value stock in the diagnostics sector, particularly due to the successful integration of ExoDx and strong performance of its Resolve test. Despite recent earnings misses, the company shows significant year-over-year growth in liquid-based test volumes.
2025-12-23 12:08:53
BTIG has reiterated its Buy rating and $7.00 price target on MDxHealth SA, citing expectations for accelerating revenue growth and adjusted EBITDA margin expansion in 2026. This target represents over 100% upside from the current price, with the company viewed as an attractive small-cap growth and value stock in the diagnostics sector. MDxHealth's acquisition of ExoDx and the strong performance of its Resolve test contribute to a positive outlook.
2025-12-08 08:08:59
Five analysts have collectively issued a "Moderate Buy" rating for MDxHealth (NASDAQ:MDXH), with an average 12-month price target of $7.75. The company's stock is currently trading at $3.60, and several firms have recently updated their price targets and ratings. MDxHealth last reported quarterly earnings of ($0.16) per share on revenue of $27.43 million, and institutional investors have been actively trading its shares.
2025-12-03 04:42:11
MDxHealth SA's stock recently dropped 28%, but it is still up 82% over the past year. The company's price-to-sales (P/S) ratio of 1.7x is low compared to the Biotech industry average of 12.1x, largely due to slower projected revenue growth of 21% annually versus the industry's 128%. This suggests investors are cautious about MDxHealth's future growth prospects, keeping its P/S ratio suppressed despite recent strong revenue increases.
